U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H13N5O5
Molecular Weight 283.2407
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARAGUANOSINE

SMILES

NC1=NC2=C(N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C(=O)N1

InChI

InChIKey=NYHBQMYGNKIUIF-FJFJXFQQSA-N
InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6+,9-/m1/s1

HIDE SMILES / InChI

Molecular Formula C10H13N5O5
Molecular Weight 283.2407
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 09:30:57 GMT 2023
Edited
by admin
on Sat Dec 16 09:30:57 GMT 2023
Record UNII
0Z99WX0GPF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARAGUANOSINE
Common Name English
ARA-GUANOSINE
Common Name English
NSC-76352
Code English
GUANINE ARABINOSIDE
Common Name English
9-.BETA.-D-ARABINOFURANOSYLGUANINE
Common Name English
2-AMINO-6-HYDROXY-9-(.BETA.-D-ARABINOFURANOSYL)PURINE
Systematic Name English
NELARABINE METABOLITE (ARA-GUANOSINE)
Common Name English
Code System Code Type Description
PUBCHEM
135499520
Created by admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID301019130
Created by admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
PRIMARY
CAS
38819-10-2
Created by admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
PRIMARY
NSC
76352
Created by admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
PRIMARY
FDA UNII
0Z99WX0GPF
Created by admin on Sat Dec 16 09:30:57 GMT 2023 , Edited by admin on Sat Dec 16 09:30:57 GMT 2023
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
BINDER->LIGAND
Plasma protein binding increased as ara-G concentrations increased.
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC SINGLE DOSE ADMINISTRATION

Tmax PHARMACOKINETIC SINGLE DOSE ADMINISTRATION